Senti Bio’s Phase 1 CAR-NK data; Allink raises $42Mnews2024-12-02T15:35:39+00:00December 2nd, 2024|Endpoints News|
Recursion reduces workforce; Oxford Nanopore teams up with UK Biobanknews2024-11-27T15:52:56+00:00November 27th, 2024|Endpoints News|
Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitornews2024-11-26T15:32:41+00:00November 26th, 2024|Endpoints News|
Replimune aims to raise $125M; Otsuka makes another deal with Ionisnews2024-11-25T15:01:27+00:00November 25th, 2024|Endpoints News|
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 datanews2024-11-21T15:49:18+00:00November 21st, 2024|Endpoints News|
Bayer, Cytokinetics make a deal in Japan; Ex-Carmot CEO to run LB Pharmaceuticalsnews2024-11-19T15:07:28+00:00November 19th, 2024|Endpoints News|
Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edemanews2024-11-18T15:16:33+00:00November 18th, 2024|Endpoints News|
Vitalli ends work on Daewoong asset; Alector’s $50M loannews2024-11-15T15:35:35+00:00November 15th, 2024|Endpoints News|
Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ optionsnews2024-11-14T15:56:45+00:00November 14th, 2024|Endpoints News|
89bio’s $125M offering; Another FDA hold for Kezarnews2024-11-13T16:10:00+00:00November 13th, 2024|Endpoints News|
